AR017440A1 - Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion - Google Patents
Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacionInfo
- Publication number
- AR017440A1 AR017440A1 ARP980106565A ARP980106565A AR017440A1 AR 017440 A1 AR017440 A1 AR 017440A1 AR P980106565 A ARP980106565 A AR P980106565A AR P980106565 A ARP980106565 A AR P980106565A AR 017440 A1 AR017440 A1 AR 017440A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- phenyl
- fpt inhibitor
- antineoplastic agent
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 3
- -1 4-piperidyl Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 108010092160 Dactinomycin Proteins 0.000 abstract 1
- 108010026389 Gramicidin Proteins 0.000 abstract 1
- 229930126263 Maytansine Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 abstract 1
- 229940123468 Transferase inhibitor Drugs 0.000 abstract 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 abstract 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 abstract 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 abstract 1
- 229960001338 colchicine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 abstract 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960000640 dactinomycin Drugs 0.000 abstract 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 abstract 1
- 229960002694 emetine Drugs 0.000 abstract 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 abstract 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229960003171 plicamycin Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229950010131 puromycin Drugs 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 239000003558 transferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US18196998A | 1998-10-29 | 1998-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017440A1 true AR017440A1 (es) | 2001-09-05 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106565A AR017440A1 (es) | 1997-12-22 | 1998-12-21 | Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (OSRAM) |
| JP (1) | JP4502503B2 (OSRAM) |
| KR (1) | KR100700907B1 (OSRAM) |
| CN (1) | CN1129431C (OSRAM) |
| AR (1) | AR017440A1 (OSRAM) |
| AT (1) | ATE317697T1 (OSRAM) |
| AU (1) | AU756762B2 (OSRAM) |
| BR (1) | BR9814419A (OSRAM) |
| CA (1) | CA2315693C (OSRAM) |
| CL (1) | CL2007001889A1 (OSRAM) |
| CO (1) | CO5080764A1 (OSRAM) |
| CZ (1) | CZ298511B6 (OSRAM) |
| DE (1) | DE69833509T2 (OSRAM) |
| DK (1) | DK1041985T3 (OSRAM) |
| ES (1) | ES2255196T3 (OSRAM) |
| HU (1) | HUP0102473A3 (OSRAM) |
| IL (1) | IL136462A0 (OSRAM) |
| MY (1) | MY137303A (OSRAM) |
| NO (1) | NO326832B1 (OSRAM) |
| NZ (1) | NZ504928A (OSRAM) |
| PE (1) | PE20000042A1 (OSRAM) |
| PT (1) | PT1041985E (OSRAM) |
| SK (1) | SK285584B6 (OSRAM) |
| TW (1) | TW581763B (OSRAM) |
| WO (1) | WO1999032114A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| AU1400401A (en) * | 1999-11-09 | 2001-06-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| EP1261348A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| CA2397253A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| CA2397475A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| AU2001239275A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| WO2001064195A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| AU2002236813A1 (en) * | 2001-01-22 | 2002-07-30 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| ES2318000T3 (es) * | 2001-02-15 | 2009-05-01 | Janssen Pharmaceutica Nv | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. |
| HUP0402401A2 (hu) * | 2001-11-30 | 2005-03-29 | Schering Corp. | Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| DE69120430D1 (de) * | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| WO1997005902A1 (fr) * | 1995-08-09 | 1997-02-20 | Banyu Pharmaceutical Co., Ltd. | Composition medicinale |
| CZ292791B6 (cs) * | 1995-12-22 | 2003-12-17 | Schering Corporation | Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění |
| US5977163A (en) * | 1996-03-12 | 1999-11-02 | Pg-Txl Company, L. P. | Water soluble paclitaxel prodrugs |
| AU715604B2 (en) * | 1996-04-03 | 2000-02-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000508661A (ja) * | 1996-04-15 | 2000-07-11 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 放射線および化学療法に対する細胞の感作 |
| WO1997038664A2 (en) * | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| EP0934270A1 (en) * | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6337992B1 (en) * | 1997-01-29 | 2002-01-08 | Philips Medical Systems Technologies Ltd. | Predictive bolus tracking |
| HUP0004326A3 (en) * | 1997-02-18 | 2003-07-28 | Canji Inc San Diego | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
-
1998
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en not_active Ceased
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60143911D1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| GEP20032896B (en) | 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment | |
| FR2678938B1 (fr) | Derives de pyrrolidine, leur preparation et les medicaments les contenant. | |
| IL80149A (en) | Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases | |
| CY1106602T1 (el) | Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| GEP20063799B (en) | Tropane derivatives useful in therapy | |
| DK0776202T3 (da) | Liposomalt indkapslet taxol, dets fremstilling af dets anvendelse | |
| FI863652A0 (fi) | 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning. | |
| ES2037086T3 (es) | Procedimiento para preparar formulaciones farmaceuticas. | |
| CY1109364T1 (el) | Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες | |
| FR2805818B1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
| CO5080764A1 (es) | Metodos para el tratamiento de enfermedades proliferativas | |
| FI895520A0 (fi) | Anti-aterosklerotiska diaryl foereningar. | |
| DK0539479T3 (da) | Heterocykliske forbindelser | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| ATE146361T1 (de) | Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs | |
| MX9203361A (es) | Composiciones farmaceuticas que contienen cloruro de galio. | |
| IL141515A (en) | Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same | |
| ITRM930286A0 (it) | Composizione farmaceutica per somministrazione rettale nel trattamentodi cefaleo e relativo metodo di preparazione ed impiego. | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
| GEP20043225B (en) | 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives | |
| ES2086526T3 (es) | Aplicacion medicinal de m-csf. | |
| YU29803A (sh) | Kombinacija kamptotekina i derivata stilbena za lečenje raka | |
| GEP20022613B (en) | Compositions with Beneficial Organoleptic Properties and Their Solvates, Method for Their Production and Pharmaceutical Compound Containing the Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |